Furthermore, this treatment lead to a restoration of the frequency of naive CD8+ T cells, and improved the de novo immune response to Influenza challenge as seen by improved survival and a higher frequency of Influenza- specific lymphocytes in the mediastinal lymph nodes. The gene discussed is CD8A; the disease is influenza.